Cihad Ozcelik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cihad Ozcelik has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Zeynep Karakoy
Department of Pharmacology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey
3 shared publications - Aysegul Tavaci Ozcelik
Department of Pharmacology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
2 shared publications - Zekai Halici
Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum 25240, Turkey
2 shared publications - Alperen Canpolat1 shared publication
- Ayse Bozkurt
Van Yuzuncu Yil University, Faculty of Pharmacy, Department of Pharmacology, 65100 Van, Turkey; Ataturk University, Faculty of Medicine, Department of Medical Pharmacology, 25240 Erzurum, Turkey
1 shared publication - Betül Sena Uyanık1 shared publication
Latest Publications
- 13 October 2026
- Published by Vizetek Publishing Company
Güncel Farmakoterapi ve Biyokimya Current Pharmacotherapy and Biochemistry
Türkiyenin E-kitap portalı Libraryturk.com aracılığıyla Güncel Farmakoterapi ve Biyokimya Current Pharmacotherapy and Biochemistry adlı kitaba erişeblirsiniz.
- 13 October 2026
- Published by Vizetek Publishing Company
Güncel Farmakoterapi ve Biyokimya Current Pharmacotherapy and Biochemistry
Türkiyenin E-kitap portalı Libraryturk.com aracılığıyla Güncel Farmakoterapi ve Biyokimya Current Pharmacotherapy and Biochemistry adlı kitaba erişeblirsiniz.
- Open Access
- 29 September 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
Investigation of maresin 1 and possible associated intracellular pathways in nasal polyp pathophysiology
- 29 September 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
Open AccessInvestigation of maresin 1 and possible associated intracellular pathways in nasal polyp pathophysiology
- 20 September 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3391-3399
Avanafil Mitigates Testicular Ischemia/Reperfusion Injury via NLRP3 Pathway Modulation in Rats
Objective: In our study, the effectiveness of avanafil, a second-generation phosphodiesterase-5 (PDE5) inhibitor, on testicular torsion (TT) related ischemia/reperfusion injury via NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), which triggers inflammatory response, are studied molecularly, biochemically and histopathologically. Material and Method: This study was performed on 24 male Wistar albino rats randomized into four groups. Testicular ischemia/reperfusion (I/R) model was created for groups 2, 3 and 4. Groups 3 and 4, respectively, were administered a dose of 5 and 10 mg/kg avanafil before reperfusion by gavage. The testicles which were left in ischemia for two hours, were detorsioned for four hours. All animals were sacrificed after reperfusion. Testicular tissues were examined molecularly, biochemically and histopathologically. Results: The NLRP3, Interleukin-1β (IL-1β) and Tumor Necrosis alpha (TNF-α) mRNA expression levels were observed to be significantly increased in the I/R group compared to the healthy group (p < 0.001). After both doses of avanafil, NLRP3, IL-1β and TNF-α mRNA expression levels, which increased as a result of I/R, decreased in both avanafil groups. (p < 0.001). The greatest decrease was seen at the dose of 10 mg/kg (p < 0.001). Increased Malondialdehyde (MDA) levels due to I/R were statistically significantly decreased in both doses of avanafil (p < 0.001). Decreased Superoxide Dismutase (SOD) levels due to I/R damage increased statistically significantly in both doses of avanafil (p < 0.001). Conclusion: It was found that avanafil can reduce the damage caused by testicular I/R and that it will find new applications in the future with the support of advanced experimental and clinical studies. Graphical Abstract
- 20 September 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3391-3399
Avanafil Mitigates Testicular Ischemia/Reperfusion Injury via NLRP3 Pathway Modulation in Rats
Objective: In our study, the effectiveness of avanafil, a second-generation phosphodiesterase-5 (PDE5) inhibitor, on testicular torsion (TT) related ischemia/reperfusion injury via NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), which triggers inflammatory response, are studied molecularly, biochemically and histopathologically. Material and Method: This study was performed on 24 male Wistar albino rats randomized into four groups. Testicular ischemia/reperfusion (I/R) model was created for groups 2, 3 and 4. Groups 3 and 4, respectively, were administered a dose of 5 and 10 mg/kg avanafil before reperfusion by gavage. The testicles which were left in ischemia for two hours, were detorsioned for four hours. All animals were sacrificed after reperfusion. Testicular tissues were examined molecularly, biochemically and histopathologically. Results: The NLRP3, Interleukin-1β (IL-1β) and Tumor Necrosis alpha (TNF-α) mRNA expression levels were observed to be significantly increased in the I/R group compared to the healthy group (p < 0.001). After both doses of avanafil, NLRP3, IL-1β and TNF-α mRNA expression levels, which increased as a result of I/R, decreased in both avanafil groups. (p < 0.001). The greatest decrease was seen at the dose of 10 mg/kg (p < 0.001). Increased Malondialdehyde (MDA) levels due to I/R were statistically significantly decreased in both doses of avanafil (p < 0.001). Decreased Superoxide Dismutase (SOD) levels due to I/R damage increased statistically significantly in both doses of avanafil (p < 0.001). Conclusion: It was found that avanafil can reduce the damage caused by testicular I/R and that it will find new applications in the future with the support of advanced experimental and clinical studies. Graphical Abstract